

New indication



and 2 cycles of platinum-doublet chemotherapy

For the treatment of metastatic NSCLC
which has not been treated with prior systemic therapy



OPDIVO®, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumor aberrations, and no prior systemic therapy for metastatic NSCLC.

Please consult the OPDIVO Product Monograph at http://www.bmscanada.ca/en/pm/OPDIVO_EN_PM.pdf and YERVOY Product Monograph at http://www.bms.com/assets/bms/ca/documents/productmonograph/YERVOY_EN_PM.pdf for indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monographs are also available by calling us at: 1-866-463-6267.

OPDIVO and YERVOY and the OPDIVO and YERVOY logos are registered trademarks of Bristol-Myers Squibb Company used under license by Bristol-Myers Squibb Canada Co.



							14983_BOP_NSCLC_JournalAd_Current-Onco_En_01						
APPROVED	GD	AD	CW	PR	PROD	CS					01		
	01	01	—	—	01	01	Format	8.5 x 11 in		Spread	NO		
							Safety	7.125 x 10 in		Bleed	8.75 x 11.25 in		
							Pub.	Journal Current Oncology (JCO)					RELEASE 06/10/20
							Copy	---					
CORR.							Langu.	English		Graphic designer	EL	[YB]	tank